GLP-1R exposure shows no causal link to most mental disorders except eating disorders
GLP-1 Receptor Agonists Show Mixed Links to Mental Health
This meta-analysis investigated the causal associations between GLP-1 receptor agonists and various mental health outcomes including anxiety…
New research explores how GLP-1 receptor agonists relate to conditions like anxiety and depression, finding no clear genetic link to most di…
Multi-target therapies may address combined hypertension and dyslipidemia pathophysiology
Multi-Target Therapies May Address Combined Hypertension and High Cholesterol
This systematic review synthesizes evidence on synergistic mechanisms of hypertension and dyslipidemia, highlighting the RAAS/PPAR axis, AMP…
Combining treatments like statins and RAAS inhibitors may offer a more precise way to manage both high blood pressure and cholesterol levels…
GLP-1 receptor agonists may reduce cognitive decline in type 2 diabetes patients with dementia
GLP-1 drugs may slow cognitive decline in type 2 diabetes
A systematic review of systematic reviews and meta-analyses found that GLP-1 receptor agonists are associated with reduced overall cognitive…
A review of reviews suggests GLP-1 drugs like Ozempic may help protect memory and thinking in people with type 2 diabetes.
Tirzepatide maximum tolerated dose leads weight reduction ranking in obesity network meta-analysis
New analysis shows weight loss drugs work best for adults with obesity without diabetes
This systematic review and network meta-analysis of 14,059 adults with obesity without diabetes ranked GLP-1 receptor agonists and a dual ag…
A large review of many studies found that specific injectable medicines help adults lose weight. Tirzepatide worked best, but all options re…
GLP-1 agonists show short-term metabolic benefit in PCOS but reproductive effects remain uncertain
Doctors suggest GLP-1 drugs help weight but need careful planning before pregnancy in PCOS
A meta-analysis of GLP-1 receptor agonists in PCOS found relatively robust support for short-term metabolic benefit, but reproductive outcom…
New analysis shows GLP-1 drugs help with weight loss for PCOS patients. However, doctors are unsure if these drugs improve fertility and nee…
GLP-1 receptor agonists show no increased ocular disorder risk in type 2 diabetes meta-analysis
New analysis shows GLP-1 drugs do not raise eye disease risk for diabetes patients
This systematic review and meta-analysis of 28 observational studies found that GLP-1 receptor agonists did not increase the risk of NAION, …
A large review of 28 studies found that diabetes drugs called GLP-1 receptor agonists do not increase the risk of eye problems like glaucoma…
GLP-1RAs show lower risk of serious liver events compared with DPP-4 inhibitors in adults with type 2 diabetes
GLP-1 drugs may lower serious liver risks compared to DPP-4 inhibitors in type 2 diabetes
This systematic review and exploratory meta-analysis evaluated incident cirrhosis or composite serious liver events among adults with type 2…
A new analysis suggests GLP-1 receptor agonists might reduce serious liver events compared to DPP-4 inhibitors for adults with type 2 diabet…
GLP-1 receptor agonists reduce major adverse limb events with HR 0.59 in PAD
New analysis shows GLP-1 drugs cut stroke risk for people with leg artery disease
This systematic review and meta-analysis of over 240,000 adults with peripheral artery disease found that GLP-1 receptor agonists significan…
A large review of real-world data found GLP-1 drugs significantly reduce stroke and heart attack risk in adults with peripheral artery disea…
Real-time CGM improved HbA1c versus SMBG in adults with type 2 diabetes on basal insulin and modern therapies
Real-time glucose monitoring improves blood sugar control in type 2 diabetes
This randomised controlled trial compared real-time continuous glucose monitoring against standard self-monitoring of blood glucose in adult…
A new trial shows continuous glucose monitoring helps lower blood sugar levels better than standard finger-prick testing for adults with typ…
Bariatric surgery yields greater long-term weight loss than GLP-1 receptor agonists in adults with obesity
Bariatric surgery leads to more weight loss than GLP-1 drugs over one year
This meta-analysis compared bariatric surgery against GLP-1 receptor agonists in adults with obesity. While weight loss differences were not…
A large analysis of 20,594 adults found bariatric surgery caused greater weight loss than GLP-1 drugs after one year, with benefits growing …
Preoperative GLP-1 agonists yield moderate weight loss before bariatric surgery, meta-analysis finds
GLP-1 drugs before weight loss surgery: modest benefit, no extra risk
This meta-analysis of 5461 patients found that preoperative GLP-1 receptor agonist use led to moderate weight reduction (SMD 0.4, 4.87 kg vs…
Taking GLP-1 drugs before bariatric surgery helps drop a few extra pounds but doesn't boost long-term weight loss or raise complication risk…
GLP-1 receptor agonists show potential benefits for metabolic dysfunction-associated steatotic liver disease with acceptable safety
Review shows GLP-1 drugs may help fatty liver disease
This umbrella review evaluated twenty-three meta-analyses and systematic reviews regarding GLP-1 receptor agonists in patients with metaboli…
A review of many studies suggests GLP-1 receptor agonists may improve fatty liver disease, but the evidence is still early and needs stronge…